[1]郭德阳,陈雷,王劲松,等.芳香化酶抑制剂用于绝经后激素依赖性乳腺癌患者新辅助内分泌治疗效果的Meta分析[J].第三军医大学学报,2016,38(07):781-786.
 Guo Deyang,Chen Lei,Wang Jinsong,et al.Aromatase inhibitors in neoadjuvant endocrine therapy for postmenopausal women with hormone-dependent breast cancer: a meta-analysis[J].J Third Mil Med Univ,2016,38(07):781-786.
点击复制

芳香化酶抑制剂用于绝经后激素依赖性乳腺癌患者新辅助内分泌治疗效果的Meta分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第07期
页码:
781-786
栏目:
公共卫生与预防医学
出版日期:
2016-04-15

文章信息/Info

Title:
Aromatase inhibitors in neoadjuvant endocrine therapy for postmenopausal women with hormone-dependent breast cancer: a meta-analysis
作者:
郭德阳陈雷王劲松余正
重庆医科大学附属永川医院普外一科
Author(s):
Guo Deyang Chen Lei Wang Jinsong Yu Zheng

First Department of General Surgery, Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China

关键词:
芳香化酶抑制剂新辅助内分泌治疗激素依赖性乳腺癌Meta分析
Keywords:
aromatase inhibitors neoadjuvant endocrine therapy neoadjuvant chemotherapy meta-analysis
分类号:
R181.23; R730.53; R737.9
文献标志码:
A
摘要:

目的       评估芳香化酶抑制剂(aromatase inhibitors,AIs)应用于绝经后激素依赖性乳腺癌患者新辅助内分泌治疗的效果及安全性。      方法      计算机检索Cochrane 图书馆、PubMed、CNKI及CBMdisc等数据库,按既定标准纳入芳香化酶抑制剂应用于新辅助内分泌治疗的随机对照试验,以Cochrane系统进行逐篇质量评价,提取资料,并采用RevMan 5.0软件进行Meta分析。      结果      共纳入9个随机对照试验,合计1 512名患者。结果显示:①在绝经后激素依赖性乳腺癌患者的新辅助内分泌治疗中,AIs在总有效率和完全缓解率上均优于雌激素受体阻滞剂;②在绝经后激素依赖性乳腺癌患者中,使用AIs的新辅助内分泌治疗效果与新辅助化疗相当;③新辅助化疗结合新辅助内分泌治疗对于绝经后激素依赖性乳腺癌患者可能有更好的近期疗效,但因研究太少,论证强度不高;④相对于细胞毒性药物,AIs和他莫昔芬的毒副反应发生率都较低,症状也较轻。      结论      AIs可以作为绝经后激素依赖性乳腺癌患者新辅助内分泌治疗的一个安全、有效的治疗方案。

Abstract:

Objective       To evaluate the efficacy and safety of aromatase inhibitors (AIs) in neoadjuvant endocrine therapy for postmenopausal patients with hormone-dependent breast cancer.       Methods       Computer retrieval was carried out in Cochrane library, PubMed, CNKI and CBMdisc database with established standards for randomized controlled trials of neoadjuvant endocrine therapy using the aromatase inhibitors, with the quality evaluation by Cochrane system. The extracted data was systematically analyzed with RevMan 5.0.       Results       There were 9 randomized controlled trials incorporated in this study, including 1 512 patients. Meta-analysis showed that ①the total effective rate and complete response rates of AIs were superior than those of estrogen receptor blockers in the neoadjuvant endocrine therapy for breast cancer; ②The neoadjuvant endocrine treatment with AIs exerted similar curative effect as neoadjuvant chemotherapy in the patients of hormone dependent breast cancer; ③New adjuvant chemotherapy combined with new adjuvant endocrine therapy might have better short-term curative effect for the disease, though the argumentation intensity was not strong enough because of too few trials; ④ AIs and tamoxifen resulted in lower incidence of adverse reaction and milder symptoms compared with the cytotoxic drugs.       Conclusion       Neoadjuvant therapy with AIs is safe and effective for postmenopausal hormone dependent breast cancer.

参考文献/References:

[1]Goldhirsch A, Winer E P, Coates A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. DOI: 10.1093/annonc/mdt303
[2]Mathew J, Asgeirsson K S, Jackson L R, et al. Neoadjuvant endocrine treatment in primary breast cancer: review of literature [J]. Breast, 2009, 18(6): 339-344. DOI: 10.1016/j.breast.2009.09.012
[3]Chia Y H, Ellis M J, Ma C X. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool[J]. Br J Cancer, 2010, 103(6): 759-764. DOI: 10.1038/sj.bjc.6605845
[4]Dixon J M, Anderson T J, Miller W R. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective[J]. Eur J Cancer, 2002, 38(17): 2214-2221. DOI: 10.1016/S0959-8049(02)00265-4
[5]张彦武, 常庆龙, 贾国丛.NCT不敏感的局部晚期乳腺癌的新辅助内分泌治疗疗效分析[J].中国普通外科杂志, 2010, 19(5): 569-571.
[6]Howell A, Cuzick J, Baum M, et al.Rseults of the ATAC(Arimidex, Tamoxifen, Alone or in Combination)trial after completion of 5 years’adjuvant treatment for breast cancer[J].Lancet, 2005, 365(9453): 60-62. DOI:  10.1016/S0140-6736(04)17666-6
[7]Makris A, Powles T J, Ashley S E, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer[J]. Ann Oncol, 1998, 9(11): 1179-1184.
[8]王永霞, 张爱玲, 张蓉, 等. 来曲唑与他莫西芬在绝经后乳腺癌新辅助内分泌治疗中的应用[J]. 南方医科大学学报, 2008, 28(4): 667-668.
[9]李荣萍, 任佳, 吕文静, 等. 来曲唑在绝经后乳腺癌新辅助内分泌治疗中的应用[J]. 山东医药, 2009, 49 (32): 67-69.
[10]芦珊, 周玮. 来曲唑在老年乳腺癌新辅助内分泌治疗中的疗效观察[J]. 实用癌症杂志, 2012, 27(6): 632-634, 637.
[11]Smith I E, Dowsett M, Ebbs S R, et al. Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial[J]. J Clin Oncol, 2005, 23(22): 5108-5116. DOI: 10.1200/JCO.2005.04.005
[12]Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study[J]. Ann Oncol, 2012, 23(12): 3069-3074. DOI: 10.1093/annonc/mds132
[13]Luigi C, Buzdar A, Noguchi S, et al. Comparison of Anastrozole versus Tamoxifen as Preoperative Therapy in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial[J]. Cancer, 2006, 106(10): 2095-2103. DOI: 10.1002/cncr.21872
[14]Semiglazov V F, Semiglazov V V, Dashyan G A, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptorpositive breast cancer[J]. Cancer, 2007, 110(2): 244-254. DOI: 10.1002/cncr.22789
[15]Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study[J]. Ann Oncol, 2001, 12(11): 1527-1532.
[16]Mohammadianpanah M, Ashouri Y, Hoseini S, et al. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase Ⅲ clinical trial[J]. Breast Cancer Res Treat, 2012, 132(3): 853-861. DOI: 10.1007/s10549-011-1814-6
[17]Albain K S, Green S J, Ravdin P M, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100(SWOG-8824)[J]. Proc Am Soc Clin Oncol, 2002, 2(1): 37-39.
[18]Hug V, Thames H, Clark J. Chemotherapy and hormonal therapy in combination[J]. J Clin Oncol, 1988, 6(1): 173-177.
[19]Bear H D, Anderson S, Smith R E, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2006, 24(13): 2019-2027. DOI: 10.1200/JCO.2005. 04.1665

相似文献/References:

[1]王家武,姜庆,樊晓栋.新辅助内分泌联合治疗与单纯根治性手术对前列腺癌预后和疗效的Meta分析[J].第三军医大学学报,2011,33(13):1388.
 Wang Jiawu,Jiang Qing,Fan Xiaodong.Prognosis and efficacy of new adjuvant combination endocrine therapy versus radical surgery for prostate cancer: a meta-analysis study[J].J Third Mil Med Univ,2011,33(07):1388.

更新日期/Last Update: 2016-04-01